Candel Therapeutics (CADL) Prepaid Assets (2020 - 2025)
Candel Therapeutics (CADL) posted Prepaid Assets of $1.7 million for Q4 2025, down 47.71% sequentially from $3.2 million in Q3 2025, and up 44.17% YoY from $1.2 million in Q4 2024.
Candel Therapeutics (CADL) Prepaid Assets (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Prepaid Assets for 6 years, with the latest figure at $1.7 million in Q4 2025.
- Quarterly Prepaid Assets rose 44.17% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (up 44.17% YoY) and the FY2025 annual result came in at $1.7 million, up 44.17% from the prior year.
- Prepaid Assets fell to $1.7 million in Q4 2025 per CADL's latest filing, from $3.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $3.2 million in Q3 2025 and troughed at $110000.0 in Q2 2021.
- A 5-year average of $1.7 million and a median of $1.5 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2021 and 2024: Prepaid Assets surged 2376.34% in 2021, then plunged 45.62% in 2024.
- Over 5 years, Prepaid Assets stood at $2.3 million in 2021, then dropped by 18.06% to $1.9 million in 2022, then declined by 26.66% to $1.4 million in 2023, then dropped by 16.91% to $1.2 million in 2024, then surged by 44.17% to $1.7 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $1.7 million, $3.2 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 3.17 Mn |
| Jun 30, 2025 | 2.92 Mn |
| Mar 31, 2025 | 983,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | 544,000.00 |
| Mar 31, 2022 | 1.33 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 2.57 Mn |
| Jun 30, 2021 | 110,000.00 |
| Dec 31, 2020 | 93,000.00 |